Clinical Efficacy and Safety of Individual Pembrolizumab Administration Based on Pharmacokinetic in Advanced Non-small Cell Lung Cancer: an Open-label, Single Arm, Exploratory Clinical Trial
The clinical trial conducted by Sun Yat-sen University explores the pharmacokinetic-guided administration of pembrolizumab in advanced non-small cell lung cancer (NSCLC). Given the established role of pembrolizumab as a standard therapy in NSCLC, this study may provide insights into optimizing dosing strategies, potentially enhancing efficacy and safety profiles. The trial's completion and its focus on pharmacokinetics could position Sun Yat-sen University favorably in the competitive landscape of immuno-oncology, particularly as personalized medicine continues to gain traction. The findings may also influence future treatment guidelines and reimbursement strategies, impacting market access for pembrolizumab and similar agents.
Indication: Non-small Cell Lung Cancer
Modality: small molecule
Target: PD-1 receptor
Sponsor: Sun Yat-sen University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-1 receptor
View original source fields
Condition raw: Non-small Cell Lung Cancer
Condition normalized: Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PD-1 receptor
Target normalized: PD-1 receptor